Overview

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Suncadia Pharmaceuticals Co., Ltd
Treatments:
Enoxaparin
Enoxaparin sodium